Ozempic, a star GLP-1, steps onto the scene as a type 2 diabetes medication, preparing for its starring role in the SUSTAIN trials
Among emerging evidence, nanoparticle-delivered GLP-1RA formulations provide compelling preclinical evidence of plaque-targeted action
It should also be noted that, from a methodological perspective, the model used (Cox with stratification by cardiovascular risk class of the trials, i.e., SURPASS-4: high risk, and all others: low risk) requires various assumptions, including the homogeneity of the relative effect of tirzepatide treatment on MACE regardless of the baseline cardiovascular risk level of the patients
The most frequent adverse events were mainly mild-to-moderate gastrointestinal events, which reduced over time."The magnitude of weight loss observed with retatrutide has the potential to slow disease progression and reshape how we treat and manage type 2 diabetes," Bajaj said in a statement.Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which is developing retatrutide and funded the study.Abstract/Full Text (subscription or payment may be required)More Information.Sign up for our weekly HealthDay newsletter
The HPLC conditions were as follows: the column was a Phenomenex HYDRO-RP column (C18, polar endcapped